Organization | Centre de Recherche Clinique du CHUS

Centre de Recherche Clinique du CHUS Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2000

NCT00223145

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

Centre de recherche du CHUS | CRC - CHUS | Fragile X Clinic, Centre de recherche du CHUS | Fragile X Research Foundation of Canada

Active Ingredients

Drugs in Phase 3 Trials (2)

bicalutamide (casodex) (1 trial)

goserelin (zoladex) (1 trial)

Drugs in Phase 2 Trials (2)

lovastatin (mevacor) (1 trial)

minocycline (minocin) (2 trials)

Drugs in Other Trials (6)

11c acetate (1 trial)

[3-3h]-glucose (1 trial)

fludeoxyglucose f-18 (1 trial)

glycerin (1 trial)

mirabegron (myrbetriq) (1 trial)

palmitic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Fragile X Syndrome (Phase 2)

Prostatic Neoplasms (Phase 3)

Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 10